TGFBR3 and breast carcinoma: The miR-107 target TGFBR3 has been indicated to be a tumor inhibitor in a few cancer kinds such as breast cancer [29], prostate cancer [30], non-small cell lung cancer [31], oral squamous cell carcinoma [32].